Clindamycin Dosing for Cellulitis
For cellulitis in adults, use clindamycin 600 mg IV every 8 hours for severe infections or 300-450 mg orally four times daily for less severe cases; in children, dose 25-40 mg/kg/day IV divided every 8 hours or 30-40 mg/kg/day orally divided every 8 hours. 1, 2
Adult Dosing
Intravenous Administration
- Severe non-purulent cellulitis: 600-900 mg every 6-8 hours IV 1
- MRSA cellulitis: 600 mg every 8 hours IV 1
- MSSA cellulitis: 600 mg every 8 hours IV 1
Oral Administration
- MRSA cellulitis: 300-450 mg four times daily 1, 2
- Serious infections: 150-300 mg every 6 hours 2
- More severe infections: 300-450 mg every 6 hours 2
Critical dosing consideration: Weight-based dosing is essential. A 2017 study demonstrated that inadequate dosing (<10 mg/kg/day) was independently associated with clinical failure (30% vs 17% failure rate, OR=2.01, p=0.032) 3. This means a 100 kg adult requires at least 1000 mg/day, which translates to approximately 300 mg four times daily minimum.
Pediatric Dosing
Intravenous Administration
- Standard dosing: 25-40 mg/kg/day divided into 3 doses every 8 hours 1
- Severe infections: 10-13 mg/kg/dose every 8 hours IV 1
Oral Administration
- MRSA cellulitis: 30-40 mg/kg/day divided into 3 doses 1
- Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses 2
- More severe infections: 16-20 mg/kg/day divided into 3-4 equal doses 2
Important: Clindamycin should be dosed based on total body weight regardless of obesity 2. Capsules are not suitable for children unable to swallow them whole; use clindamycin palmitate oral solution instead 2.
Renal Impairment
No dose adjustment is required for renal impairment, including severe renal failure 2, 4. The elimination half-life increases only slightly with markedly reduced renal function, and serum levels remain well above the minimum inhibitory concentration for sensitive pathogens 4. Less than 1% of bioactivity is excreted in urine in severe renal failure, and the drug is not removed by hemodialysis 4.
However, in patients with severe renal failure, some modification to dosage would be prudent and should be monitored by measuring serum levels 4.
Hepatic Impairment
No specific dose adjustment is provided in the FDA label 2. The elimination half-life increases slightly in patients with markedly reduced hepatic function 2, but dosage schedules do not need routine modification 2.
Special Populations
Elderly Patients
No dose adjustment necessary for elderly patients with normal hepatic function and normal (age-adjusted) renal function 2. The elimination half-life increases to approximately 4 hours (vs 3.2 hours in younger adults), but the extent of absorption is unchanged 2.
Obese Patients
Dose based on total body weight 2. Clindamycin clearance and volume of distribution, normalized by total body weight, are comparable regardless of obesity 2.
Duration of Therapy
- Standard cellulitis: 7 days, depending on clinical response 1
- β-hemolytic streptococcal infections: Continue for at least 10 days 2
Critical Warnings
Drug Interactions
When combined with rifampicin, oral clindamycin is contraindicated 5. Rifampicin increases clindamycin clearance by 3-fold and dramatically reduces bioavailability (from 56% to 4-11% depending on rifampicin dose) 5. If this combination is necessary, use IV clindamycin at doses of at least 3600-4800 mg/day by continuous infusion 5.
Administration
- Take capsules with a full glass of water to avoid esophageal irritation 2
- Discontinue if significant diarrhea occurs (risk of Clostridioides difficile colitis) 2
Monitoring
For severe renal or hepatic impairment, monitor serum clindamycin levels to ensure therapeutic concentrations are maintained 4.